Kuala Lumpur, Malaysia- May 26th 2011: SIOGEN Biotech, the world leader in the production of Silane-based NanoVesicles, has been awarded the ‘Most Innovative Biotech in Asia Award’ for 2011. Presented at the BioPharma Industry Asia Awards in Singapore, held in conjunction with the 4th Annual BioPharma Asia Convention, the award recognises SIOGEN’s state of the art drug targeting and delivery technology Siosomes® and potential impact in the global pharmaceutical market.
Dr. Shermal Perera, Managing Director of SIOGEN, said, “Winning this award is further validation that Siosomes® can enable the improved, targeted delivery of a broad range of therapeutic agents. It is an exciting time for SIOGEN as our technology and creative partnering have led to a pipeline of smart therapeutics with indications in diseases ranging from tuberculosis to cancer. We are currently seeking joint venture partners and investment to set up our operations in the US, to expand our NanoVesicle technology into other markets.”
Nominations were invited from across the industry and more than 40,000 votes were cast to decide the award winners. In the ‘Most Innovative Biotech’ category, five companies were shortlisted on the basis of their innovation and novel approach in developing drugs. SIOGEN was voted the winner for its Siosomes® NanoVesicle platform technology and the creative collaborations it has established with research institutions, pharma and biotech companies worldwide.
Siosomes® have a large repertoire of constructs with different characteristics that allow a range of drug carrier NanoVesicles to enable active agents to be targeted and delivered to organs and tissues in the body that were previously impossible to reach. Available in different sizes, SIOGEN has GMP manufactured about 45 different Siosomes® with specific inherent characteristics containing antibody, peptide, negative, positive and inert properties. Ideal for problematic therapeutic agents, Siosomes® can reduce toxicity, extend half-life and allow new routes of administration.
SIOGEN, one of Malaysia’s leading biotechnology companies, is based in Kuala Lumpur, with a research centre in Scotland, GMP manufacturing centres in Germany and plans to establish footprints in the United States and Brazil. The company has developed its Siosomes® technology over the last 12 years in Germany and during this period secured funding and drug development partnerships on a global scale, with research hospitals in the United States and top pharma companies. However it was grants from the Malaysian government, through the Ministry of Science and Biotech Corp, that allowed SIOGEN to develop its business, invest in its pre-commercialisation activities and reach the global stage.
Contacts
SIOGEN Biotech
Dr Shermal Perera, MD
+603 79878903
+6012 6871826
or
College Hill Life Sciences
Dimithri Wignarajah
+44 (0)20 78667858
siogen@collegehill.com
About SIOGEN Biotech
SIOGEN Biotech (http://www.siogen.com), a world leader in the production of silane-based nanoparticles, has developed Siosomes® as flexible vesicles for the targeted delivery of drugs and other compounds and substances. It is applying its nanoparticle technology to reduce side effects and increase efficacy of existing and developmental drugs. Siosomes® are nanoparticle vesicles consisting of two or more concentric, organo-silicon layers based on the Silane (SiH4) general structure. These can be manufactured in different sizes, dependent on use and requirements, ranging from 40nm – 1500nm in size. SIOGEN welcomes enquiries from potential partners that have problem compounds, for which the Siosomes® delivery technology can address toxicity, extend half-life, improve targeting, or provide new routes of administration. The Company is a privately financed technology company, located in Kuala Lumpur, Malaysia, with a research centre in the UK and manufacturing facilities in Germany.
